GSK:BCBA
Glaxosmithkline CEDEAR
၁၉,၃၆၀.၀၀ ARS
arrow_upward
+၂.၉၂%(+၅၅၀.၀၀) 1D
ဇွန် ၄, GMT-၃ ၁၇:၀၀:၀၀ · ARS
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
၁၉,၃၃၀.၀၀ ARS
High
၁၉,၃၆၀.၀၀ ARS
Low
၁၉,၁၉၀.၀၀ ARS
Mkt. cap
ဋေ ၁.၀၄ သ
Avg. vol.
၅၁၇.၀၀
Volume
၁.၁၆ ထောင်
52-wk high
၂၂,၇၆၀.၀၀ ARS
52-wk low
၁၁,၁၅၀.၀၀ ARS
Shares outstanding
၄၀၅.၀၃ ဋေ
No. of employees
၇ သောင်း
Open
၁၉,၃၃၀.၀၀ ARS
High
၁၉,၃၆၀.၀၀ ARS
Low
၁၉,၁၉၀.၀၀ ARS
Mkt. cap
ဋေ ၁.၀၄ သ
Avg. vol.
၅၁၇.၀၀
Volume
၁.၁၆ ထောင်
52-wk high
၂၂,၇၆၀.၀၀ ARS
52-wk low
၁၁,၁၅၀.၀၀ ARS
Shares outstanding
၄၀၅.၀၃ ဋေ
No. of employees
၇ သောင်း
News stories
From sources across the web
AD HOC NEWS
·
ပြီးခဲ့သည့် ၅ နာရီ
GSK plc stock (GB0009252882): shares edge higher after Jefferies healthcare conference appearance
The Globe and Mail
·
ပြီးခဲ့သည့် ၁ ရက်
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth
Kalkine Media
·
ပြီးခဲ့သည့် ၁ ရက်
Why Healthcare Shares Keep Their Cool Through The Noise
Traders Union
·
ပြီးခဲ့သည့် ၃ ရက်
What is behind GSK stock's recent drop in value today
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About Glaxosmithkline CEDEAR
CEOEmma Walmsley | Emma Walmsley
Employees၆.၆၈ သောင်း
Founded၂၀၀၀ ဒီ ၂၇
Headquarters-
Sector-
Websitegsk.com
AI content may include mistakes. Learn more